Sonoma Pharmaceuticals, headquartered in Boulder, Colorado, develops hypochlorous acid products for various healthcare applications and went public on January 26, 2007. Their product lineup includes Lumacyn, Regenacyn, and MicrocynAH for skin and wound care.
SNOA has been in the news recently: Sonoma Pharmaceuticals, Inc. has regained compliance with Nasdaq's $1.00 minimum bid price following a reverse stock split, effective September 19, 2024. Additionally, Hill Physicians Medical Group has partnered with MarinHealth Medical Center and UCSF Health to expand HMO options for residents in Marin and Sonoma counties, providing access to over 300 physicians.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
